Concepedia

Publication | Open Access

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

DOIFull Paper Access

414

Citations

31

References

2019

Year

Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Lindberg, Ildiko Lingvay, ANETTE L. SØNDERGAARD, Marianne Bach Treppendahl, Eduard Montanya
Diabetes Care

Abstract

Oral semaglutide was superior to empagliflozin in reducing HbA<sub>1c</sub> but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA<sub>1c</sub> and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.

References

YearCitations

Page 1